Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Related Articles
Prophylactic Management of IRRs With Amivantamab Plus Lazertinib for NSCLC
Panelists discuss other adverse events associated with amivantamab and lazertinib beyond infusion-related reactions.
Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia
Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.
I-SPY2 Trial Highlights Treatment for Rare Breast Cancer… : Oncology Times
An abstract is unavailable.
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.
Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders
In this video, Tanya Siddiqi, MD, City of Hope, Duarte, CA, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, and Alexey Danilov, MD, PhD, City…
Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma
Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.
Reporting immunoglobulin gene analysis in CLL: updates to the ERIC guidelines
Anastasia Chatzidimitriou, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses updates to the European Research Initiative on CLL (ERIC) recommendations on how to…
Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS
SELECT-MDS-1 will be discontinued after failing to meet its primary end point of improved CR rates with tamibarotene/azacitidine in high-risk, RARA+ MDS.
Episode 19 | How to Write a Strong Commercialization Plan – Part 1.
In part one of the three-part series on writing a strong commercialization plan, NCI SBIR Program Director William Bozza invites NCI SBIR-funded biotech innovators, Sid…
Biosimilar SCT510 Has Similar Efficacy and Safety as Bevacizumab in NSCLC
Phase 3 data revealed similar safety and efficacy outcomes with SCT510 and bevacizumab.
